| scholarly article | Q13442814 |
| P2093 | author name string | Robert H Eckel | |
| Ira J Goldberg | |||
| Nicholas A Di Prospero | |||
| Debapriya Basu | |||
| Adam E Mullick | |||
| Lesley-Ann Huggins | |||
| Joseph Obunike | |||
| Paul L Rothenberg | |||
| Diego Scerbo | |||
| P2860 | cites work | Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats | Q24563606 |
| A simple method for the isolation and purification of total lipides from animal tissues | Q25939009 | ||
| Angiopoietin-like 4 mediates PPAR delta effect on lipoprotein lipase-dependent fatty acid uptake but not on beta-oxidation in myotubes | Q27316586 | ||
| Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes | Q42404578 | ||
| Fenofibrate lowers plasma triglycerides and increases LDL particle diameter in subjects with type 2 diabetes. | Q43903170 | ||
| Nonfasting triglycerides and risk of ischemic stroke in the general population | Q44734713 | ||
| Streptozotocin-Treated High Fat Fed Mice: A New Type 2 Diabetes Model Used to Study Canagliflozin-Induced Alterations in Lipids and Lipoproteins | Q46386699 | ||
| Determining hepatic triglyceride production in mice: comparison of poloxamer 407 with Triton WR-1339. | Q46581287 | ||
| Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes | Q46818617 | ||
| Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes | Q47373645 | ||
| CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis. | Q51707689 | ||
| Nonfasting Triglycerides and Risk of Myocardial Infarction, Ischemic Heart Disease, and Death in Men and Women | Q61162458 | ||
| Lipoprotein lipase activity and mRNA levels in bovine tissues | Q61479847 | ||
| Canagliflozin | Q87226535 | ||
| Characterization of the fasting-induced adipose factor FIAF, a novel peroxisome proliferator-activated receptor target gene | Q28138952 | ||
| The direct peroxisome proliferator-activated receptor target fasting-induced adipose factor (FIAF/PGAR/ANGPTL4) is present in blood plasma as a truncated protein that is increased by fenofibrate treatment | Q28266376 | ||
| Angiopoietin-like protein 4 converts lipoprotein lipase to inactive monomers and modulates lipase activity in adipose tissue | Q28272732 | ||
| Induction of cardiac Angptl4 by dietary fatty acids is mediated by peroxisome proliferator-activated receptor beta/delta and protects against fatty acid-induced oxidative stress | Q28279283 | ||
| The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice | Q28552063 | ||
| Common variants associated with plasma triglycerides and risk for coronary artery disease | Q28659915 | ||
| The failing heart--an engine out of fuel | Q29617881 | ||
| Inhibition of cardiac lipoprotein utilization by transgenic overexpression of Angptl4 in the heart. | Q33819755 | ||
| Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes | Q34673134 | ||
| Lipolysis, and not hepatic lipogenesis, is the primary modulator of triglyceride levels in streptozotocin-induced diabetic mice. | Q34734402 | ||
| n-3 fatty acids and serum lipoproteins: human studies | Q34739799 | ||
| Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus | Q34876148 | ||
| Effect of diabetes and insulin of the maximum capacity of the renal tubules to reabsorb glucose | Q35184196 | ||
| Amelioration of Hyperglycemia with a Sodium-Glucose Cotransporter 2 Inhibitor Prevents Macrophage-Driven Atherosclerosis through Macrophage Foam Cell Formation Suppression in Type 1 and Type 2 Diabetic Mice | Q35852679 | ||
| Phlorizin: a review | Q35995949 | ||
| SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study | Q36820604 | ||
| Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease | Q36851336 | ||
| Cardiac Myocyte KLF5 Regulates Ppara Expression and Cardiac Function | Q36950315 | ||
| Insulin stimulation of adipose tissue lipoprotein lipase. Use of the euglycemic clamp technique | Q36983181 | ||
| Inactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease | Q36988623 | ||
| Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study | Q37022726 | ||
| Rescue of heart lipoprotein lipase-knockout mice confirms a role for triglyceride in optimal heart metabolism and function | Q37439763 | ||
| Diabetes and diabetes-associated lipid abnormalities have distinct effects on initiation and progression of atherosclerotic lesions | Q37486465 | ||
| Myocardial fatty acid metabolism in health and disease | Q37677921 | ||
| Hyperglycemia promotes myelopoiesis and impairs the resolution of atherosclerosis | Q37711215 | ||
| Repression of glucocorticoid-stimulated angiopoietin-like 4 gene transcription by insulin | Q37716367 | ||
| Biology of human sodium glucose transporters | Q37870037 | ||
| Effects of dapagliflozin on cardiovascular risk factors | Q38113098 | ||
| Update on marine omega-3 fatty acids: management of dyslipidemia and current omega-3 treatment options | Q38146202 | ||
| The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE -/- mice fed a western diet | Q38730067 | ||
| Triglyceride Treatment in the Age of Cholesterol Reduction | Q38932760 | ||
| Preservation of myocardial fatty acid oxidation prevents diastolic dysfunction in mice subjected to angiotensin II infusion | Q39331891 | ||
| Empagliflozin, via Switching Metabolism Toward Lipid Utilization, Moderately Increases LDL Cholesterol Levels Through Reduced LDL Catabolism | Q39748114 | ||
| Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. | Q41895967 | ||
| Muscle-derived angiopoietin-like protein 4 is induced by fatty acids via peroxisome proliferator-activated receptor (PPAR)-delta and is of metabolic relevance in humans | Q42065841 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | lipoprotein | Q28350 |
| triglyceride | Q186319 | ||
| P304 | page(s) | 2207-2216 | |
| P577 | publication date | 2018-09-01 | |
| P1433 | published in | Arteriosclerosis, Thrombosis, and Vascular Biology | Q4797542 |
| P1476 | title | Mechanism of Increased LDL (Low-Density Lipoprotein) and Decreased Triglycerides With SGLT2 (Sodium-Glucose Cotransporter 2) Inhibition | |
| P478 | volume | 38 |
| Q90448877 | Clinical relevance between sodium-glucose co-transporter 2 inhibitors and lipid profiles in Asian patients with type 2 diabetes mellitus: a systematic review with a meta-analysis of randomized controlled trials |
| Q89537944 | Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence |
| Q90111552 | Mechanisms and Evidence for Heart Failure Benefits from SGLT2 Inhibitors |
| Q92576546 | Rationale, Design for the ASSET Study: A Prospective Randomized Study Comparing Empagliflozin's Effect to Sitagliptin on Cardiac Fat Accumulation/Function in Patients with Type 2 Diabetes |
| Q91906202 | SGLT-2 inhibitors as promising therapeutics for non-alcoholic fatty liver disease: pathophysiology, clinical outcomes, and future directions |
| Q89567932 | The effect of dapagliflozin on apolipoprotein B and glucose fluxes in patients with type 2 diabetes and well-controlled plasma LDL cholesterol |
Search more.